Anti-CCAR1 autoantibodies are specific for anti-TIF1γ-positive dermatomyositis and decrease cancer risk relative to the general population.
David FiorentinoChristopher A MecoliTak IgusaJemima AlbaydaJulie J PaikEleni TiniakouBrittany AdlerAndrew Lee MammenAmi A ShahAntony RosenLisa Christopher-StineLivia A Casciola-RosenPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Anti-CCAR1 autoantibodies are specific for anti-TIF1-γ-positive dermatomyositis. Their presence in anti-TIF1-γ-positive patients attenuates the risk of cancer to a level comparable to that seen in the general population.